Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating

Raymond James analyst Ryan Deschner has maintained a Buy rating on SPRY stock, citing regulatory setbacks for rival Anaphylm that enhance ARS Pharmaceuticals’ competitive position in the epinephrine market. The FDA's identification of deficiencies in Anaphylm's NDA increases the likelihood of delays in its commercialization. Deschner notes that safety concerns raised in ARS’s Citizen Petition align with FDA's issues, potentially postponing Anaphylm's launch beyond key demand periods. These factors support Deschner's bullish outlook on SPRY shares, as ARS is poised to capture greater market opportunities.